Tissue regeneration and transplantation of solid organs involve complex processes that can only be studied in the context of the living organism, and methods of analyzing these processes in vivo are essential for development of effective transplantation and regeneration procedures. We utilized in vivo bioluminescence imaging (BLI) to noninvasively visualize engraftment, survival, and rejection of transplanted tissues from a transgenic donor mouse that constitutively expresses luciferase. Dynamic early events of hematopoietic reconstitution were accessible and engraftment from as few as 200 transplanted whole bone marrow (BM) cells resulted in bioluminescent foci in lethally irradiated, syngeneic recipients. The transplantation of autologous pancreatic Langerhans islets and of allogeneic heart revealed the tempo of transplant degeneration or immune rejection over time. This imaging approach is sensitive and reproducible, permits study of the dynamic range of the entire process of transplantation, and will greatly enhance studies across various disciplines involving transplantation.
A dvances in immunology and stem cell biology have given impetus to systematic investigation aimed at the restoration of functional organs by cell and tissue transplantation. Imaging strategies that noninvasively reveal cell viability and functional information in the context of the living body can accelerate effective development of new methods that would prolong survival of grafts and enhance regeneration of tissues. One of the cornerstone technologies in the field of molecular imaging, in vivo BLI, is based on the observations that light passes through mammalian tissues and that the expression of luciferase is detectable as an internal biological source of light in the living body (1) (2) (3) . A variety of gene transfer tools have been developed to deliver the luciferase reporters to cells (4 -7) and employed with BLI to elucidate the spatiotemporal trafficking patterns of lymphocytes within the body (4, 5) , to follow hematopoietic engraftment by transplanted luciferaseexpressing stem cells over time (6) , and to examine stem cell engraftment in cardiac tissue (7) .
To assess survival and regeneration using BLI, it is essential that the transplant constitutively and uniformly expresses luciferase throughout the study period. To date, gene transfer efficiency remains as an obstacle, especially for primary cells, tissues and intact organs, and stable reporter expression in particular cell types over time can be variable. Thus, current methods of introducing reporter genes are not satisfactory for transplantation studies. In contrast, cells from a transgenic mouse with a stably integrated reporter gene cassette controlled by a promoter that is largely constitutively expressed meet these criteria and would provide a source of uniformly labeled biological materials for transplantation studies. Here, we report the generation of a "universal donor" transgenic mouse line that incorporates a luciferase reporter driven by a constitutive promoter, and demonstrate in a series of transplantation experiments the ease and success of monitoring transplanted cells, tissue and organs in unlabeled recipient mice.
The transgene in this line is comprised of a CMV-␤-actin promoter (8) and a biscistronic gene consisting of two reporter genes, firefly luciferase and enhanced green fluorescence protein (eGFP), separated by a 2A ribosome slippage site from foot and mouth disease virus (FMDV), to allow equimolar expression of two open reading frames in cultured cells (9) (Fig. 1A) . Comparison of homozygous and heterozygous mice in this FVB.lucϩ line, designated as L2G85, indicated that both the bioluminescent and fluorescent signals in the heterozygote were lower than those in homozygote ( Fig.  1B and C) . While GFP is expressed mainly in skin (Fig. 1D) , BLI of dissected tissues showed that luciferase is expressed in heart, spleen, muscle, pancreas, skin, thymus, and BM ( Fig.  1E and data not shown).
To enable the assessment of multilineage hematopoietic reconstitution originating from a small number of BM cells, hematopoietic lineages need to express a detectable level of luciferase to permit monitoring by BLI. We therefore quantified the bioluminescence of purified hematopoietic subsets. Splenocytes were sorted by flow cytometry and then analyzed for luciferase expression in live cell assays and as cell lysates in a standard luciferase assay. Although they usually produced light less intensively immediately after sorting, sorted cells recovered after incubation at 37°C for 4 -12 hr and exhibited varying levels of luciferase activity in all leukocyte subsets tested, including CD4 ϩ and CD8 ϩ T cells, B220 Fig. 2A) . Light production of different subsets ranged from 0.02 to 0.14 photons/second/cell in the live cell assay after 12 hr in the incubator and 0.15 to 1.30 photons/second/cell in the lysate assay ( Fig. 2A) . Luciferase activity is not detected at significant levels in mature erythrocytes (Ter119
, but low levels of activity are detected in erythrocyte precur- 
sors. Isolated c-Kit
ϩ Thy-1.1 lo Lineage Ϫ Sca-1 ϩ (KTLS) hematopoietic stem cells (HSCs) express luciferase at the highest level among the different hematopoietic cell types, with 3 photons/second/cell in live cell assays (10) . The differences in light emission between the live cell and the lysate assays of the same number of isolated cells may be due to insufficient ATP levels in the sorted live cells since there are excess amounts of ATP and a CoA enzyme in the lysate assay. The consistent pattern of activity between the two assays indicates that the live cell assay reflects relative expression levels in each cell type.
To test if we could visualize the dynamics of hematopoietic engraftment from whole BM cells of this transgenic line and how the kinetics of reconstitution from whole BM differ from that of highly purified KTLS HSCs (10), 5 million whole BM cells were transplanted into lethally irradiated syngeneic recipients. Bioluminescent signal was detected from the splenic area 15 min after cell transfer (data not shown). Images obtained at 1 day posttransplant indicated signals primarily from the spleen (Fig.  2B) . Three days later, four views of the animals revealed intense signals from the bones, most likely from the marrow, and secondary lymphoid organs, spleen and lymph nodes. Hematopoietic reconstitution, measured by integrated whole body photon emission, rapidly progressed (Fig. 2B) . Engraftment from luc ϩ BM peaked at 5 weeks Transplanted bioluminescent cardiac allograft showed a decrease in light production over time by 12 days after transplantation. L2G85 mice were bred with a GFP transgenic line (GFPU). Cardiac allografts from the offsprings of this breeding (FVB) were transplanted into Balb/c recipients and all acutely rejected by 12 days. Correlating with decrease in light production, immunohistochemistry shows a decline in viable cardiomyocyte structure and an increase in inflammatory cells. In the lower panel of histology pictures, red, inflammatory cells (CD45 stain); green, cardiomyocyte (GFP); blue, nuclei (DAPI stain) (magnificationϭ400ϫ).
after transplantation, and remained high thereafter (Fig.  2C) . To confirm the presence of significant numbers of donor-derived hematopoietic cells in the recipients, we sorted myeloid and lymphoid cells from peripheral blood. In vitro luciferase assays of these sorted cells showed that there were significant numbers of donor-derived peripheral blood cells and that hematopoietic reconstitution was multilineage (data not shown). We did not observe transplant rejection in these syngeneic models, as based on the reporter activity.
To assess whether engraftment of small numbers of cells in BM could be detected, we transferred 200 whole BM cells into lethally irradiated syngeneic recipients along with 3ϫ 10 5 nontransgenic helper BM cells. Bioluminescent foci were detected at 12 to 17 days posttransplant most frequently at anatomic sites corresponding to the location of the spleen, skull, vertebrae and femurs (Fig. 2D and data  not shown) . Confirmation of tissue origin was obtained by imaging from different views and in some instances, immediately postmortem. Surprisingly, we detected bioluminescent foci arising from engrafting cells in 12% of recipients who had received 200 BM cells each. This suggests that the foci observed may be derived from both HSCs and hematopoietic progenitors since the HSC frequency in BM is usually about 0.01% (11) .
Transplantation of pancreatic islets into patients suffering from type 1 diabetes mellitus has become increasingly applied but ascertaining the presence and quantity of beta cells has proven difficult (12) . BLI has been used to track lentiviral vector transduced human or mouse islets after transplantation (13) (14) (15) . Since a transgenic donor with uniform integration sites could potentially offer greater signal stability, we purified Langerhans islets from L2G85 pancreas (16) for transplantation. These islets emitted significant amounts of bioluminescence (Fig. 3A) . When five hundred of these islets were transferred into a non-transgenic syngeneic recipient via portal vein injection, high levels of bioluminescence over the abdominal region of the liver were detected within 24 hr (Fig. 3B) . Monitoring abdominal bioluminescence of the recipient for more than 90 days revealed a decline over time that was best described by a power law equation (Fig. 3C) . Islet transplantation under the kidney capsule of syngeneic mice produced comparable results whereas allogeneic recipients rejected the grafts within 3 weeks (data not shown). The decline of bioluminescent signal over time in the syngeneic recipient could be due to islet primary nonfunction occuring with high frequency in islet transplant models (17) or to a gradual loss of luciferase gene expression in the transplanted islets since the bioluminescent signal remains stable in NOD-scid mice (14) . Further research needs to analyze the reason(s) for the decline. Nevertheless, BLI offers the possibility, in conjunction with conventional assays, to rapidly evaluate the efficacy of therapeutic strategies to improve islet transplantation.
Hearts from the L2G85 mice also exhibit bioluminescence that can serve as a marker for survival and rejection of transplants. When transplanted in an acute rejection model (18) into the abdominal cavity (19) of Balb/c mice, i.e. across a major MHC mismatch barrier, all L2G85 cardiac allografts were acutely rejected by 12 days. Light production from the cardiac allografts correlated with their viability, as it gradually declined over time after transplantation (Fig. 3D) . L2G85 mice were bred with a GFP transgenic line (FVB.Cg-Tg(GFPU)5Nagy) (20) to generate luciferase-GFP double transgenic mice L2G85XGFPU. Hearts of these double transgenic mice were rejected after transplantation with kinetics identical to those of L2G85 transplants. The course of rejection was corroborated by immunohistochemical analysis of transplanted hearts of L2G85XGFPU demonstrating an increase of inflammatory cell infiltration and a decrease in the number of viable cardiomyocytes with time during the acute rejection phase (Fig. 3D) .
Future applications of BLI with luciferase transgenic mice are distributed widely across biomedical fields. While the studies presented here demonstrate the use of this luciferase transgenic mice as a highly useful donor for tracking transplanted cells, tissues and organs, realization of the full potential of this system may greatly benefit the study of the physiological behavior and function of transplanted cells, tissue and organs, and the evaluation of new transplantation protocols in an rapid and reliable fashion.
